Knowledge

Clinical and Pharmacological Applications of Rasagiline Mesylate: A Comprehensive Review

What Is Rasagiline Mesylate?

Rasagiline mesylate is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor that plays a central role in the management of Parkinson's disease (PD). Its primary mechanism involves inhibiting the breakdown of dopamine by MAO-B within the central nervous system, thereby enhancing synaptic dopamine concentrations in the striatum. This pharmacological action directly addresses the dopaminergic deficit characteristic of PD. With approximately 14-fold greater selectivity for MAO-B over MAO-A, rasagiline offers a targeted and safer profile, minimizing hypertensive crises associated with dietary tyramine ("cheese effect").

Fig.1 Structure of rasagiline mesylate. Figure 1. The structure of rasagiline mesylate^[1].

Alfa Chemistry provides pharmaceutical-grade rasagiline mesylate, a white to off-white crystalline powder with high solubility in water, ethanol, and DMSO, suitable for formulation and bioavailability studies.

Recommended Products

Catalog Number	Product Name	Price
PI161735791	Rasagiline Mesylate	Inquiry

How Is Rasagiline Mesylate Used in Parkinson's Disease?

Rasagiline mesylate is used as monotherapy in the initial stages of Parkinson's disease and as an adjunct to levodopa in later stages of the disease. In early PD, rasagiline mesylate has been shown to slow disease progression and improve motor performance. Its use as an add-on therapy has demonstrated significant reductions in "off" time and improved "on" time without troublesome dyskinesia. In a multicenter, double-blind, placebo-controlled trial, fluctuating Parkinson's patients receiving either 0.5, 1 or 2 mg/day of rasagiline experienced a 23% reduction in Unified Parkinson's Disease Rating Scale (UPDRS) scores versus 8.5% in the placebo group^[2]. The effect lasted up to 6 weeks post-treatment, suggesting a long-lasting effect of the compound. Rasagiline mesylate also maintained a benign side effect profile with adverse events similar to placebo.

Table 1. Summary of Rasagiline Mesylate Clinical Applications

Indication	Therapeutic Role	Dose	Remarks
Early-stage Parkinson's disease	Monotherapy	1 mg/day	Improves motor symptoms
Advanced Parkinson's disease	Adjunct to levodopa	0.5–2 mg/day	Reduces "off" time, enhances "on" duration
MSA-P (investigational)	Symptom relief	1 mg/day	Improves motor/autonomic functions
Neuroprotection	Disease modification (potential)	—	Mitochondrial & anti-apoptotic pathways

What Are the Neuroprotective Effects of Rasagiline Mesylate?

Beyond symptomatic relief, rasagiline mesylate exerts significant neuroprotective effects. It prevents the dissipation of mitochondrial membrane potential and activates key signaling pathways such as the PKC-MAP kinase cascade, which are essential in neuronal survival. It also modulates apoptotic regulators by upregulating anti-apoptotic proteins like Bcl-2 and downregulating pro-apoptotic proteins such as Bax. Intriguingly, its metabolic byproducts—particularly aminoindan derivatives—demonstrate additional neuroprotective activity by enhancing mitochondrial function and reducing oxidative stress. These properties potentially position rasagiline as a disease-modifying agent rather than a purely symptomatic one.

Fig.2 Neuroprotective-antiapoptotic mechanisms of rasagiline and its anti-Alzheimer's disease derivative (a), the cholinesterase-monoamine oxidase inhibitor TV3326, and their signal transduction pathways mediating PKC-dependent neuroprotection and plasticity activation (b). Figure 2. Neuroprotective-antiapoptotic mechanisms of rasagiline and its anti-Alzheimer's disease derivative (a), the cholinesterase-monoamine oxidase (ChE-MAO) inhibitor TV3326, and their signal transduction pathways mediating PKC-dependent neuroprotection and plasticity activation (b)^[3].

How Does Rasagiline Mesylate Compare to Other MAO Inhibitors?

A major differentiating feature of rasagiline mesylate, compared to older MAO inhibitors such as selegiline, is its lack of amphetamine-like metabolites, which reduces the risk of insomnia, agitation, and cardiovascular stimulation. Additionally, the chemical structure also results in a longer half-life of MAO-B inhibition and better pharmacokinetics (fast absorption and increased biotransformation by the liver, without food interference).

Fig.3 Chemical structure of selegiline and rasagiline and their metabolites. Figure 3. Chemical structure of selegiline and rasagiline and their metabolites. Aminoindan, a metabolite of rasagiline, has neuroprotective function, in contrast to (R)-methamphetamine produced from selegiline^[4].

What Are the Known Adverse Effects and Drug Interactions?

Rasagiline mesylate is generally well tolerated. Common side effects include gastrointestinal disturbances (nausea, dry mouth, constipation), CNS effects (dizziness, somnolence, insomnia, hallucinations), cardiovascular symptoms (orthostatic hypotension, palpitations), and psychiatric disturbances (impulse control disorders, depression). When co-administered with levodopa, synergistic effects on dopamine levels can enhance both therapeutic benefit and dopaminergic side effects. However, rasagiline does not exacerbate hypertensive crises when consumed with tyramine-rich foods, unlike non-selective MAO inhibitors.

The compound is metabolized predominantly in the liver and excreted via urine. It is contraindicated in patients on meperidine, tramadol, or other MAO inhibitors due to serotonin syndrome risk.

FAQs ABout Rasagiline Mesylate

1. Can rasagiline mesylate be used alone without levodopa?

Yes, it is effective as monotherapy in early-stage Parkinson's disease and delays the need for levodopa initiation.

2. Does rasagiline cause the "cheese effect"?

No, due to its selectivity for MAO-B and lack of MAO-A inhibition, rasagiline does not potentiate tyramine-induced hypertension.

3. What is the usual time to onset of clinical effect?

Improvements in motor symptoms are generally observed within a few weeks of treatment initiation.

4. Are there any dietary restrictions with rasagiline?

Unlike non-selective MAO inhibitors, rasagiline does not require strict dietary tyramine restrictions.

5. How is rasagiline stored for stability?

To maintain chemical stability and pharmacological potency, rasagiline mesylate should be stored at –20°C.

Alfa Chemistry is at the forefront of the pharmaceutical industry, specializing in the development and supply of active pharmaceutical ingredients (APIs). We have carefully selected a number of specialty APIs of exceptional quality. Please browse the product list below to find the product you need.